TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25512422

Group type: EXPERIMENTAL
Intervention: Rifapentine (600 mg) with bedaquiline (400 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rifampin (600 mg) with bedaquiline (400 mg)
Number of subjects: 0
Study: 25512442

Group type: EXPERIMENTAL
Intervention: Counseling about sexual activity after AMI
Number of subjects: 3499
Study: 25512630

Group type: EXPERIMENTAL
Intervention: Telaprevir, Pegylated Interferon, and Ribavirin
Number of subjects: 15
Study: 25512839

Group type: EXPERIMENTAL
Intervention: Massage therapy (three weekly sessions for four weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Conventional occlusal splint therapy (worn for four weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Massage + Conventional occlusal splint therapy (three weekly sessions for four weeks and occlusal splint worn for four weeks)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Silicone occlusal splint therapy (worn for four weeks)
Number of subjects: 60
Study: 25512874

Group type: EXPERIMENTAL
Intervention: Closed loop with diluted insulin aspart (CL_Dil; 20 IU/mL)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Closed loop with standard aspart (CL_Std; 100 IU/mL)
Number of subjects: 11
Study: 25514063

Group type: EXPERIMENTAL
Intervention: Benzodiazepine users
Number of subjects: 482

Group type: COMPARATOR
Intervention: Benzodiazepine nonusers
Number of subjects: 482
Study: 25514102

Group type: EXPERIMENTAL
Intervention: Klinefelter syndrome males
Number of subjects: 73
Study: 25514320

Group type: EXPERIMENTAL
Intervention: Ten-dimensional control signals for prosthetic hand shape (three-dimensional translation, 3D orientation, four-dimensional hand shaping)
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Calibration with the presence of an object during grasping
Number of subjects: 1
Study: 25514427

Group type: EXPERIMENTAL
Intervention: High IL-8 levels (H group, n = 133)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: Low IL-8 levels (L group, n = 335)
Number of subjects: 468

Group type: EXPERIMENTAL
Intervention: High IL-8 levels (H group)
Number of subjects: 468
Study: 25515275

Group type: EXPERIMENTAL
Intervention: Poor sleep quality (measured by the Pittsburgh Sleep Quality Index)
Number of subjects: 213
Study: 25515841

Group type: EXPERIMENTAL
Intervention: First-pass contrast-enhanced cardiac MR myocardial perfusion imaging during adenosine-induced hyperaemia
Number of subjects: 6
Study: 25516773

Group type: COMPARATOR
Intervention: Paracetamol/naproxen (n = 35)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Paracetamol/CR oxycodone for 24 hours (n = 35)
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Paracetamol/CR oxycodone for 48 hours (n = 35)
Number of subjects: 105
Study: 25516774

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg once daily
Number of subjects: 219

Group type: COMPARATOR
Intervention: Diclofenac sustained release 75 mg once daily
Number of subjects: 219
Study: 25516890

Group type: EXPERIMENTAL
Intervention: MK-2206 at 135 mg weekly and selumetinib at 100 mg once daily
Number of subjects: 0
Study: 25517807

Group type: EXPERIMENTAL
Intervention: Mandarin Chinese version of the Leicester Cough Questionnaire (LCQ-MC)
Number of subjects: 144
Study: 25518027

Group type: EXPERIMENTAL
Intervention: Virtual Nutri Plus®
Number of subjects: 10

Group type: COMPARATOR
Intervention: Dietpro 5i®
Number of subjects: 10
Study: 25518864

Group type: EXPERIMENTAL
Intervention: S-100B bulk release
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: NSE at 72 hours
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Combination of Morris-Marshall score and S-100B bulk release
Number of subjects: 48
Study: 25519706

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 0
Study: 25519705

Group type: EXPERIMENTAL
Intervention: Compensation methods
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Disruption correction
Number of subjects: 325

Group type: COMPARATOR
Intervention: Friction correction
Number of subjects: 325
Study: 25519810

Group type: EXPERIMENTAL
Intervention: Bimatoprost 0.01% once daily
Number of subjects: 295
Study: 25520557

Group type: EXPERIMENTAL
Intervention: Hypnosis followed by six weeks of self-hypnosis using digital media
Number of subjects: 0

Group type: COMPARATOR
Intervention: SCD education (Control)
Number of subjects: 0
Study: 25520807

Group type: EXPERIMENTAL
Intervention: Collaborative care (patient phone-based self-management support, care management, and guideline dissemination to practices delivered by a plan-level care manager)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual care from their provider
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 344

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 344
Study: 25521292

Group type: EXPERIMENTAL
Intervention: Suprachoroidal retinal prosthesis
Number of subjects: 3
Study: 25521357

Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab and first-line paclitaxel with favorable genetic profile (VEGFR-2 rs11133360 and IL-8 rs4073)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Combination of bevacizumab and first-line paclitaxel with unfavorable genetic profile (VEGFR-2 rs11133360 and IL-8 rs4073)
Number of subjects: 113
Study: 25521398

Group type: EXPERIMENTAL
Intervention: Dacomitinib at 45 mg once daily
Number of subjects: 55
Study: 25521573

Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (CLE)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: CLE scoring system
Number of subjects: 79
Study: 25521639

Group type: EXPERIMENTAL
Intervention: Hypothermic machine preservation (HMP)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Static cold storage (SCS)
Number of subjects: 31
Study: 25521773

Group type: EXPERIMENTAL
Intervention: Standard intraoperative dose of morphine
Number of subjects: 219
Study: 25522180

Group type: EXPERIMENTAL
Intervention: ChAd63-MVA CS (5×10^9 vp)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ChAd63-MVA CS (5×10^10 vp)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ChAd63 CS
Number of subjects: 24
Study: 25522809

Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with past obesity
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with tobacco exposure
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with abnormal levels of transaminases
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with diabetes
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with male gender
Number of subjects: 905

Group type: EXPERIMENTAL
Intervention: Cirrhosis patients with older age
Number of subjects: 905
Study: 25523532

Group type: EXPERIMENTAL
Intervention: Absorb bioresorbable vascular scaffold (Absorb BVS)
Number of subjects: 51
Study: 25523604

Group type: EXPERIMENTAL
Intervention: Green tea gel (test group)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo gel (control group)
Number of subjects: 48
Study: 25524487

Group type: EXPERIMENTAL
Intervention: T1DM
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control
Number of subjects: 54
Study: 25524686

Group type: EXPERIMENTAL
Intervention: Presurgical levels of circulating CD41(+) PMPs
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Presurgical levels of circulating CD235a(+) RMPs
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Hemoglobin (HGB) levels
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Activated partial thromboplastin time (aPTT)
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Model's discriminating ability
Number of subjects: 122
Study: 25524795

Group type: EXPERIMENTAL
Intervention: Anamorelin hydrochloride 50 mg once-daily for 12 weeks
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo once-daily for 12 weeks
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Anamorelin
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study: 25524800

Group type: EXPERIMENTAL
Intervention: Blinatumomab (9 μg/day for the first 7 days and 28 μg/day thereafter) by continuous intravenous infusion over 4 weeks every 6 weeks (up to five cycles)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: Blinatumomab
Number of subjects: 189
Study: 25525182

Group type: EXPERIMENTAL
Intervention: (18)F-NOS PET/CT imaging after endotoxin instillation (4 ng/kg)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: (18)F-NOS PET/CT imaging
Number of subjects: 7
Study: 25525693

Group type: EXPERIMENTAL
Intervention: Comparative effectiveness research approaches
Number of subjects: 5400

Group type: EXPERIMENTAL
Intervention: Cross sectional comprehensive outcome assessments
Number of subjects: 5400

Group type: EXPERIMENTAL
Intervention: Longitudinal assessments
Number of subjects: 5400

Group type: EXPERIMENTAL
Intervention: Advanced neuroimaging and genomic and biomarker data
Number of subjects: 5400

Group type: EXPERIMENTAL
Intervention: Data and sample repositories
Number of subjects: 5400
Study: 25525828

Group type: EXPERIMENTAL
Intervention: Improved biomass stove
Number of subjects: 1415

Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas stoves
Number of subjects: 1415

Group type: COMPARATOR
Intervention: Traditional cooking (control)
Number of subjects: 1415
Study: 25526232

Group type: EXPERIMENTAL
Intervention: IBU(Na) 512 mg (equivalent to 400 mg IBU free acid); n = 362
Number of subjects: 891

Group type: EXPERIMENTAL
Intervention: Standard IBU 400 mg; n = 342
Number of subjects: 891

Group type: COMPARATOR
Intervention: Placebo; n = 187
Number of subjects: 891
Study: 25526776

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) 55 mg/m² per day and methotrexate 15 mg/m² per week
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine (6MP) and methotrexate
Number of subjects: 30
Study: 25526948

Group type: EXPERIMENTAL
Intervention: Advanced AMD
Number of subjects: 164

Group type: COMPARATOR
Intervention: Control (no AMD)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: All groups (adjusted for age and refractive error)
Number of subjects: 164
Study: 25527007

Group type: EXPERIMENTAL
Intervention: wXELIRI (weekly irinotecan 90 mg/m² on day 1 and capecitabine 1200 mg/m² twice daily on days 1-5)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: wXELIRI (weekly irinotecan and capecitabine)
Number of subjects: 52
Study: 25527236

Group type: EXPERIMENTAL
Intervention: Plasma calprotectin concentrations in T2DM patients
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Plasma calprotectin concentrations in T2DM patients with MetS
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Plasma calprotectin concentrations in T2DM patients with autonomic neuropathy
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Plasma calprotectin concentrations in T2DM patients with peripheral arterial disease (PAD)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Plasma calprotectin concentrations in T2DM patients with myocardial ischemia (MI)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Plasma calprotectin as a predictor of CVD, MI, autonomic neuropathy, or PAD
Number of subjects: 305
Study: 25527417

Group type: EXPERIMENTAL
Intervention: Temsirolimus
Number of subjects: 40
Study: 25527564

Group type: EXPERIMENTAL
Intervention: Assessment of T cell surface marker expression by flow cytometry and clonality by polymerase chain reaction.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Evaluation of intracellular cytokines and blood counts over 1-2 months.
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Bone marrow and skin biopsies during different parts of the cycle.
Number of subjects: 4
Study: 25527568

Group type: EXPERIMENTAL
Intervention: Clonal heterogeneity in patients with abnormal karyotype
Number of subjects: 1403

Group type: EXPERIMENTAL
Intervention: Clonal heterogeneity in unfavorable karyotype group
Number of subjects: 1403
Study: 25527663

Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Non-users (control group)
Number of subjects: 157
Study: 25527677

Group type: EXPERIMENTAL
Intervention: Lower-carbohydrate diet
Number of subjects: 99

Group type: COMPARATOR
Intervention: Lower-fat diet
Number of subjects: 99
Study: 25527748

Group type: EXPERIMENTAL
Intervention: VLDL-triacylglycerol 16:1n-7 molar percentage
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: DNL index (ratio of 16:0 to 18:2n-6)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 18:2n-6 levels
Number of subjects: 24
Study: 25527752

Group type: EXPERIMENTAL
Intervention: Total fish consumption (≤2.0-3.0 servings/wk)
Number of subjects: 71458

Group type: EXPERIMENTAL
Intervention: Fatty fish consumption (0.6-2.0 servings/wk)
Number of subjects: 71458

Group type: EXPERIMENTAL
Intervention: Lean fish consumption (0.6-2.0 servings/wk)
Number of subjects: 71458
Study: 25527756

Group type: EXPERIMENTAL
Intervention: CML-AGE consumption (highest quintile)
Number of subjects: 528251

Group type: EXPERIMENTAL
Intervention: Red meat consumption (highest quintile)
Number of subjects: 528251

Group type: COMPARATOR
Intervention: CML-AGE consumption (lowest quintile)
Number of subjects: 528251
Study: 25527757

Group type: EXPERIMENTAL
Intervention: Habitual sleep duration
Number of subjects: 14906
Study: 25527759

Group type: EXPERIMENTAL
Intervention: Palmitic acid (16:0)
Number of subjects: 3004

Group type: EXPERIMENTAL
Intervention: Stearic acid (18:0)
Number of subjects: 3004

Group type: EXPERIMENTAL
Intervention: Oleic acid (18:1n-9)
Number of subjects: 3004

Group type: EXPERIMENTAL
Intervention: Vaccenic acid (18:1n-7)
Number of subjects: 3004

Group type: EXPERIMENTAL
Intervention: Other fatty acid biomarkers and estimated dietary SFAs or MUFAs
Number of subjects: 3004
Study: 25527763

Group type: EXPERIMENTAL
Intervention: 16:1n-9
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 20:3n-6
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 22:5n-3
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Ratio of 18:2n-6 to 18:3n-3
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: 18:3n-3
Number of subjects: 203
Study: 25527907

Group type: EXPERIMENTAL
Intervention: RECIST 1.1
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Continuous-scale tumour size
Number of subjects: 464
Study: 25529193

Group type: EXPERIMENTAL
Intervention: BI 831266 (130 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BI 831266 (various doses 4-130 mg)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BI 831266 (various doses)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: BI 831266 (32 mg)
Number of subjects: 25
Study: 25529339

Group type: EXPERIMENTAL
Intervention: Low dose MSCs (1 million cells/kg PBW)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intermediate dose MSCs (5 million cells/kg PBW)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: High dose MSCs (10 million cells/kg PBW)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: All doses of MSCs
Number of subjects: 9
Study: 25529544

Group type: EXPERIMENTAL
Intervention: Metabolically abnormal but normal-weight (MHO)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Metabolically healthy obese (MHO)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Metabolically abnormal obese
Number of subjects: 250

Group type: COMPARATOR
Intervention: Metabolically healthy normal-weight (MHNW)
Number of subjects: 250
Study: 25529885

Group type: EXPERIMENTAL
Intervention: 96-well rapid equilibrium dialysis (RED) method
Number of subjects: 0
Study: 25530131

Group type: EXPERIMENTAL
Intervention: Dasatinib 100 mg once daily
Number of subjects: 52
Study: 25531297

Group type: EXPERIMENTAL
Intervention: Cool Challenge (18°C for ≤120 min) in tetraplegics
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Baseline (27°C) in tetraplegics
Number of subjects: 14

Group type: COMPARATOR
Intervention: Cool Challenge (18°C for ≤120 min) in able-bodied controls
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline (27°C) in able-bodied controls
Number of subjects: 14
Study: 25531808

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) injection in forearm and deltoid
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intramuscular (IM) injection in deltoid
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) injection in forearm
Number of subjects: 102
Study: 25531894

Group type: EXPERIMENTAL
Intervention: Rabbit antithymocyte globulin (rATG)
Number of subjects: 33
Study: 25531960

Group type: EXPERIMENTAL
Intervention: ALO-02 (oxycodone-hydrochloride/naltrexone-hydrochloride)
Number of subjects: 395
Study: 25532016

Group type: EXPERIMENTAL
Intervention: Normocaloric Low Cholesterol Diet (NLCD) for 30 days
Number of subjects: 0
Study: 25532039

Group type: EXPERIMENTAL
Intervention: Klinefelter syndrome patients
Number of subjects: 132

Group type: COMPARATOR
Intervention: Male controls
Number of subjects: 132

Group type: COMPARATOR
Intervention: Female controls
Number of subjects: 132
Study: 25532044

Group type: EXPERIMENTAL
Intervention: Baseline leptin levels
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Baseline IGF-I levels
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Baseline iPTH levels
Number of subjects: 633

Group type: EXPERIMENTAL
Intervention: Baseline adiponectin levels
Number of subjects: 633
Study: 25532471

Group type: EXPERIMENTAL
Intervention: Sunitinib treatment before surgery
Number of subjects: 72
Study: 25533035

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 102
Study: 25533729

Group type: EXPERIMENTAL
Intervention: Twelve-week weight loss intervention, details on dosage and specific methods not provided.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Neuroimaging using Functional Magnetic Resonance Imaging (fMRI) during food and non-food image viewing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up during a 6-month maintenance period after the weight loss intervention.
Number of subjects: 0
Study: 25533886

Group type: EXPERIMENTAL
Intervention: SBT/ABPC 3 g QID intravenously for 3-14 days
Number of subjects: 47
Study: 25533902

Group type: EXPERIMENTAL
Intervention: Wii.n.Walk intervention (Nintendo Wii Fit)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Attention control group (Wii Big Brain cognitive software)
Number of subjects: 3
Study: 25534573

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg
Number of subjects: 1821

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1821
Study: 25535009

Group type: EXPERIMENTAL
Intervention: A homozygotes of rs10779646
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: G allele of rs7549184
Number of subjects: 590

Group type: EXPERIMENTAL
Intervention: STAR*D dataset
Number of subjects: 590
Study: 25535041

Group type: EXPERIMENTAL
Intervention: HIV medication adherence intervention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prior published studies
Number of subjects: 0
Study: 25535294

Group type: EXPERIMENTAL
Intervention: US smokers; urine NNAL excretion
Number of subjects: 441

Group type: COMPARATOR
Intervention: Chinese smokers; urine PAH metabolites (fluorene, phenanthrene, pyrene)
Number of subjects: 441
Study: 25535398

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT) added to standard therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intraoperative radiotherapy (IORT)
Number of subjects: 0
Study: 25536209

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) surgery
Number of subjects: 25
Study: 25537783

Group type: EXPERIMENTAL
Intervention: Increasing quartiles of neighbourhood greenspace
Number of subjects: 10476

Group type: EXPERIMENTAL
Intervention: Highest quartile of neighbourhood greenspace
Number of subjects: 10476

Group type: COMPARATOR
Intervention: None specified
Number of subjects: 10476
Study: 25538134

Group type: EXPERIMENTAL
Intervention: Medium-HDI countries
Number of subjects: 9301

Group type: EXPERIMENTAL
Intervention: High-HDI countries
Number of subjects: 9301

Group type: EXPERIMENTAL
Intervention: Very-high HDI countries
Number of subjects: 9301

Group type: EXPERIMENTAL
Intervention: Lower-income/middle-income countries
Number of subjects: 9301

Group type: EXPERIMENTAL
Intervention: High-income countries
Number of subjects: 9301
Study: 25538176

Group type: EXPERIMENTAL
Intervention: ipilimumab plus fotemustine
Number of subjects: 86
Study: 25538323

Group type: EXPERIMENTAL
Intervention: Exogenous intravenous administrations of GLP-1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous intravenous administrations of GIP
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exogenous intravenous administrations of GLP-1 and GIP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 25538794

Group type: EXPERIMENTAL
Intervention: Sepsis survivors (78 subjects)
Number of subjects: 1152

Group type: COMPARATOR
Intervention: Sepsis non-survivors (28 subjects)
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: VPS9D1 gene variants in sepsis survivors
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: General gene expression analysis
Number of subjects: 1152

Group type: EXPERIMENTAL
Intervention: Functional genetic variants
Number of subjects: 1152
Study: 25538907

Group type: EXPERIMENTAL
Intervention: Total epithelium off
Number of subjects: 22

Group type: COMPARATOR
Intervention: Partial epithelial removal
Number of subjects: 22
Study: 25539270

Group type: EXPERIMENTAL
Intervention: Combined CT angiography (CTA) and perfusion CT
Number of subjects: 381

Group type: COMPARATOR
Intervention: SPECT
Number of subjects: 381

Group type: COMPARATOR
Intervention: Diagnostic catheter angiography
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Combined CTA and perfusion CT
Number of subjects: 381
Study: 25540064

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/day (n = 63)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/day (n = 28, CP 2L)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/day (n = 7, advanced-phase 2L)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Bosutinib 500 mg/day (n = 11, 3L)
Number of subjects: 63
Study: 25540406

Group type: EXPERIMENTAL
Intervention: Preterm milk
Number of subjects: 22

Group type: COMPARATOR
Intervention: Term milk
Number of subjects: 22
Study: 25540981

Group type: EXPERIMENTAL
Intervention: Isocaloric diet
Number of subjects: 8
Study: 25541100

Group type: EXPERIMENTAL
Intervention: Attenuated MPS II patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 20
Study: 25541444

Group type: EXPERIMENTAL
Intervention: Iliofemoral vein stent placement
Number of subjects: 62